AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PRESCIENT THERAPEUTICS LTD

0.041

0.000

Volume:480.25K

Turnover:19.77K

Market Cap:43.11M

PE:-4.51

High:0.042

Open:0.040

Low:0.040

Close:0.041

52wk High:0.063

52wk Low:0.037

Shares:1.05B

Float Shares:863.70M

Volume Ratio:0.55

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.009

EPS(LYR):-0.009

ROE:-49.72%

ROA:-26.95%

PB:3.79

PE(LYR):-4.51

Loading ...

Overview Company News Filings

BRIEF-Prescient Therapeutics Seeks Trading Halt

Prescient Therapeutics - Raises a$6.8 Mln in Share Purchase Plan

THOMSON REUTERS

Prescient Therapeutics Ltd-Prescient Announces Results of Spp & Launches Placement

THOMSON REUTERS

Prescient Therapeutics - Enters Trading Halt for Follow-on Placement at a$0.04 per Share

THOMSON REUTERS

Prescient Therapeutics Completes Initiation Visit at US Site

MT Newswires Live

Notification of cessation of securities - PTX-PTX.AX

Notification of cessation of securities - PTX-PTX.AX

Prescient Share Purchase Plan Investor Presentation-PTX.AX

ASX ALERT-Prescient Therapeutics Opens Share Purchase Plan-PTX.AX

BRIEF-Prescient Therapeutics To Raise A$7 Million

Proposed issue of securities - PTX-PTX.AX

ASX ALERT-Prescient Therapeutics Launches Share Purchase Plan for $7m-PTX.AX

Prescient Doses First Patient in White Blood Cell Cancer Treatment Candidate Trial; Shares Rise 4%

MT Newswires Live

Prescient Therapeutics Receives Fast Track FDA Designation for Potential Lymphoma Treatment; Shares Up 5%

MT Newswires Live

BUZZ-Australia's Prescient Therapeutics gains on FDA fast-track status for cancer drug

BRIEF-Prescient Therapeutics' PTX-100 Receives U.S. FDA Fast Track Designation

Prescient Therapeutics Completes First Site Initiation Visit for Cancer Treatment Candidate Trial; Shares Up 7%

MT Newswires Live

Prescient Therapeutics Appoints Chief Medical Officer; Shares Down 4%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PTX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","market":"AU","secType":"STK","nameCN":"PRESCIENT THERAPEUTICS LTD","latestPrice":0.041,"timestamp":1757657520000,"preClose":0.041,"halted":0,"volume":480247,"delay":0,"nameEN":"PRESCIENT THERAPEUTICS LTD","floatShares":863697911,"shares":1051514543,"eps":-0.009099,"marketStatus":"Not Yet Opened","change":0,"latestTime":"09-12 16:12:00 AEST","open":0.04,"high":0.042,"low":0.04,"amount":19772,"amplitude":0.04878,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.009099,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1757894400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.041,"openAndCloseTimeList":[[1757635200000,1757656800000]],"volumeRatio":0.5516343295449435,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PTX.AU\",,,,,undefined,":{"symbol":"PTX.AU","floatShares":863697911,"roa":"-26.95%","roe":"-49.72%","lyrEps":-0.009092,"volumeRatio":0.5516343295449435,"shares":1051514543,"dividePrice":0,"high":0.042,"amplitude":0.04878,"preClose":0.041,"low":0.04,"week52Low":0.037,"pbRate":"3.79","psRate":"9.90","week52High":0.063,"institutionHeld":0,"latestPrice":0.041,"eps":-0.009099,"divideRate":0,"volume":480247,"delay":0,"ttmEps":-0.009099,"open":0.04,"prevYearClose":0.05,"prevWeekClose":0.041,"prevMonthClose":0.041,"prevQuarterClose":0.044,"fiveDayClose":0.04,"twentyDayClose":0.046,"sixtyDayClose":0.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2555070040","title":"BRIEF-Prescient Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2555070040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555070040?lang=en_us&edition=fundamental","pubTime":"2025-07-29 09:06","pubTimestamp":1753751188,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics Seeks Trading Halt July 29 (Reuters) - Prescient Therapeutics Ltd PTX.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON  CAPITAL RAISEFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nFWN3TP26D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2555776702","title":"Prescient Therapeutics - Raises a$6.8 Mln in Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2555776702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555776702?lang=en_us&edition=fundamental","pubTime":"2025-07-29 07:54","pubTimestamp":1753746895,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUE98CYQL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2555702775","title":"Prescient Therapeutics Ltd-Prescient Announces Results of Spp & Launches Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2555702775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555702775?lang=en_us&edition=fundamental","pubTime":"2025-07-29 07:54","pubTimestamp":1753746895,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUE98CYQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2555027727","title":"Prescient Therapeutics - Enters Trading Halt for Follow-on Placement at a$0.04 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2555027727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555027727?lang=en_us&edition=fundamental","pubTime":"2025-07-29 07:54","pubTimestamp":1753746895,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUE98CYQL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTX.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2551152621","title":"Prescient Therapeutics Completes Initiation Visit at US Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2551152621","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551152621?lang=en_us&edition=fundamental","pubTime":"2025-07-16 09:48","pubTimestamp":1752630522,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  has completed a site initiation visit at the VCU Massey Comprehensive Cancer Center in Virginia for its ongoing Phase 2a clinical trial of drug candidate PTX-100 in patients with relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.Additional US sites are expected to be initiated in the coming weeks, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LENZ","BK7067","BK7508","PTX.AU","BK4139","BK4007"],"gpt_icon":0},{"id":"2551730719","title":"Notification of cessation of securities - PTX-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2551730719","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551730719?lang=en_us&edition=fundamental","pubTime":"2025-07-14 11:33","pubTimestamp":1752464008,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250714:nASXbq8yj3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nASX7PBwf6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PTX.AU","BK7067"],"gpt_icon":0},{"id":"2549598318","title":"Notification of cessation of securities - PTX-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2549598318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549598318?lang=en_us&edition=fundamental","pubTime":"2025-07-08 10:00","pubTimestamp":1751940011,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250708:nASX9MkVPl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nASXy356Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PTX.AU"],"gpt_icon":0},{"id":"2548333302","title":"Prescient Share Purchase Plan Investor Presentation-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548333302","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548333302?lang=en_us&edition=fundamental","pubTime":"2025-07-04 07:19","pubTimestamp":1751584763,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250703:nASX9JZ7D5","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nASX262Mb0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PTX.AU","BK7067"],"gpt_icon":0},{"id":"2548354836","title":"ASX ALERT-Prescient Therapeutics Opens Share Purchase Plan-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548354836","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548354836?lang=en_us&edition=fundamental","pubTime":"2025-07-02 07:21","pubTimestamp":1751412096,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250701:nASX1jyFRD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nASX8bWFR4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTX.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2548046430","title":"BRIEF-Prescient Therapeutics To Raise A$7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2548046430","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548046430?lang=en_us&edition=fundamental","pubTime":"2025-07-01 07:26","pubTimestamp":1751325987,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics To Raise A$7 MillionJuly 1 (Reuters) - Prescient Therapeutics Ltd PTX.AX:TO RAISE A$7 MILLION VIA A SHARE PURCHASE PLAN AT A$0.040 PER SHAREFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX14X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2548462260","title":"Proposed issue of securities - PTX-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548462260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548462260?lang=en_us&edition=fundamental","pubTime":"2025-07-01 07:10","pubTimestamp":1751325044,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX287WSg","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX708S3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2548046240","title":"ASX ALERT-Prescient Therapeutics Launches Share Purchase Plan for $7m-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548046240","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548046240?lang=en_us&edition=fundamental","pubTime":"2025-07-01 07:10","pubTimestamp":1751325026,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX8yFZV9","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASX8p6bzP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2538487409","title":"Prescient Doses First Patient in White Blood Cell Cancer Treatment Candidate Trial; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2538487409","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538487409?lang=en_us&edition=fundamental","pubTime":"2025-05-27 10:20","pubTimestamp":1748312448,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics (ASX:PTX) has dosed the first patient in its phase 2a clinical study of cancer treatment candidate PTX-100, a compound with the ability to block an important cancer growth enzym","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","PTX.AU","BK7508"],"gpt_icon":0},{"id":"2528329537","title":"Prescient Therapeutics Receives Fast Track FDA Designation for Potential Lymphoma Treatment; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528329537","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528329537?lang=en_us&edition=fundamental","pubTime":"2025-04-17 12:18","pubTimestamp":1744863516,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  received a fast-track designation from the US Food and Drug Administration for its PTX-100 compound for the potential treatment of adults with relapsed or refractory mycosis fungoides, according to a Wednesday filing with the Australian bourse.The designation will expedite the review of therapies for serious conditions with high unmet need, enabling earlier delivery to patients, the filing said.Mycosis fungoides is a subtype of cutaneous T-cell lymphoma, a group of rare blood cancers affecting the skin.Shares rose nearly 5% in afternoon trade Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BFXG0V08.USD","LENZ","BK4139","PTX.AU","BK7067","BK4104","IE00B5TLWC47.USD","BK7508","BK4585","BK4007","FAST","BK4588","IE00BYQQ9H92.USD","BK4567"],"gpt_icon":0},{"id":"2527401260","title":"BUZZ-Australia's Prescient Therapeutics gains on FDA fast-track status for cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2527401260","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527401260?lang=en_us&edition=fundamental","pubTime":"2025-04-16 09:35","pubTimestamp":1744767341,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Prescient Therapeutics gains on FDA fast-track status for cancer drug** Shares of Prescient Therapeutics PTX.AX rise as much as 28.6% to A$0.054, hit their highest levels since February 11** The clinical-stage oncology co says it received the US FDA Fast-Track designation for PTX-100, a treatment for adults with relapsed or refractory mycosis fungoides** PTX-100 is a compound with the ability to block an important cancer growth enzyme, says co** The fast-track status is an important step towards commercialisation of the drug, says co** About 2.7 million shares change hands, 4.3 times the 30-day average volume of shares** Stock down 16% this year, as of last close  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nL4N3QU034:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTX.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2527547722","title":"BRIEF-Prescient Therapeutics' PTX-100 Receives U.S. FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527547722","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527547722?lang=en_us&edition=fundamental","pubTime":"2025-04-16 08:00","pubTimestamp":1744761636,"startTime":"0","endTime":"0","summary":"BRIEF-Prescient Therapeutics' PTX-100 Receives U.S. FDA Fast Track DesignationApril 16 (Reuters) - Prescient Therapeutics Ltd PTX.AX:PTX-100 RECEIVES U.S. FDA FAST TRACK DESIGNATIONFurther company coverage: PTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QT2HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTX.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2522866954","title":"Prescient Therapeutics Completes First Site Initiation Visit for Cancer Treatment Candidate Trial; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522866954","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522866954?lang=en_us&edition=fundamental","pubTime":"2025-03-26 10:52","pubTimestamp":1742957523,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics (ASX:PTX) completed the first site initiation visit of its phase 2a clinical study of cancer treatment candidate PTX-100, according to a Wednesday filing with the Australian bou","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LENZ","BK4139","BK7508","PTX.AU"],"gpt_icon":0},{"id":"2521731388","title":"Prescient Therapeutics Appoints Chief Medical Officer; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2521731388","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521731388?lang=en_us&edition=fundamental","pubTime":"2025-03-24 09:56","pubTimestamp":1742781393,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  appointed Marissa Lim as Chief Medical Officer, effective Monday, according to a same-day filing with the Australian bourse.Lim succeeds CMO Terrence Chew, who will continue with the company in an advisory capacity, per the filing.The clinical-stage oncology company's shares were down 4% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTX.AU","XKO.AU","BK7067","LENZ","XAO.AU","XJO.AU","BK7508","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}]}}